Search

Pharmanet claims burns trial success

LEEDERVILLE-BASED Pharmanet Group Ltd has announced positive results from research into its protein fragment drug, which inhibits reaction to UVB burns. The research shows that the drug, CS-104, suppresses the normal biological response to UVB burning most significantly when applied within five minutes of the injury. The work has been carried out by Pharmanet’s drug discovery subsidiary Cambridge Scientific Pty Ltd, which has been working on acute injury cascade mediators for almost two years. Pharmanet’s drug discovery program was recently expanded to include additional in vitro programs, which are to be undertaken by independent scientists at government-supported medical research facilities in Perth.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Transactions

04/10/13
$0 Bought
04/10/13
$0 Bought
04/10/13
$0 Bought
Total value as at the date of the transaction
Source: Morningstar

BNiQ Disclaimer